Last reviewed · How we verify
NCT06103669: VALOROUS
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
NA trial testing Ablative local therapy in Breast Cancer in 250 participants. Currently enrolling.
5 December 2025
Quick facts
| Lead sponsor | University of California, Davis |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 250 |
| Start date | 5 October 2023 |
| Primary completion | 5 December 2025 |
| Estimated completion | 5 January 2031 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ablative local therapy
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Oligoprogressive — all drugs for Oligoprogressive →
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Sarcoma — all drugs for Sarcoma →
Sponsor
University of California, Davis
Who can join
18 and older, any sex, with Breast Cancer or Oligoprogressive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives.
Merloni F, Palleschi M, Gianni C, Sirico M, et al · · 2024 · cited 3× · PMID 39312051 · DOI 10.1007/s10585-024-10312-3
Verify or expand the search:
- PubMed search for NCT06103669
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ablative local therapy
Trials testing the same drug.
- NCT06101277 — Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) · NA · recruiting
- NCT06101290 — Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) · NA · recruiting
- NCT06103682 — LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE) · NA · recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of California, Davis trials
Trials by the same sponsor.
- NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
- NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
- NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
- NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
- NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06103669 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
- Last refreshed: 17 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06103669.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing